1500 Bull Lea Road
+1 859 977 8600
Piramal Pharma Solutions is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end services required to bring a drug to the market place faster. You may reach out to team Piramal by clicking here
We offer Pharmaceutical Development and Manufacturing solutions through collaborative partnership models and we work with our customers throughout the drug life cycle.
We have created a vast network of Development and Manufacturing facilities located in North America, Europe and Asia that offers a multitude of services covering the entire drug life cycle, from Drug Discovery & Development to Commercial Manufacturing of off-patent Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.
Our Development centers & Manufacturing sites have accreditations from regulatory bodies in US, Europe & Japan. With a pool of 450 scientists, including 100 Ph.d’s across the Globe we are committed to Research & Development programs. We offer specialized services such as Antibody Drug Conjugation and are well versed in technologies such as Bio-catalysis.
At Piramal Solutions, we are moving towards becoming a ‘Customer Centric’ organization by focusing on the “Pulse of the Customer”. We are evaluating various ways to improve our internal processes, communications, and program management in order to improve our delivery commitments and service levels.
This division features among the top 10 contract drug manufacturers in the world as per report released by UN Conference on Trade and Development and recently in March 2014 we won two awards for “Quality” and “Reliability” in the CRO/CMO by Life Science Leaders.
Piramal Pharma Solutions is covered recently in the C&EN Magazine's main cover story on Pharmaceutical Outsourcing. Click here to read complete story. https://t.co/JDuqsUgwVM pic.twitter.com/bCw8vH6gDS— Piramal Pharma (@PiramalPharma) July 12, 2018